Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner.
Level 5 - mechanism / opinion, no new human data
Preclinical animal interventional study.
PubMed 38979132 · doi:10.1101/2024.06.21.599604
What was done
Researchers evaluated the effects of long-term administration of the NAD+ precursor nicotinamide mononucleotide (NMN) on male and female mice, assessing lifespan, frailty, physical activity, gene expression patterns, adipose accumulation, metabolic health, gut microbiota, and tumor burden/severity.
What was found
In both male and female mice, chronic NMN treatment increased physical activity, preserved more youthful gene expression, reduced frailty, and enriched levels of the gut bacterium *Anaerotruncus colihominis* without increasing tumor counts or severity. Effects on metabolism and longevity showed clear sex specificity: NMN slowed late-life adipose accumulation and improved metabolic health in male mice but not females, whereas female mice experienced an 8.5% increase in median lifespan that was not observed in males.
Why it matters
This study provides evidence that chronic NMN treatment can extend mammalian lifespan and delay frailty in a sex-dependent manner without accelerating tumorigenesis, highlighting the need to evaluate NAD+ boosters across both sexes.
Limits
The abstract does not state the sample sizes, mouse strain, dosage, or route/duration of NMN administration. The findings are restricted to a mouse model, have not been demonstrated in humans, and are reported in a preprint that has not undergone formal peer review.
Cited by
- supports Nicotinamide mononucleotide (NMN) improves health in old mice and extends mouse lifespan, particularly in females.